LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

LLY

1,107.56

-0.17%↓

JNJ

206.85

+0.04%↑

ABBV

226.94

-2.17%↓

UNH

329.51

+1.13%↑

AZN

93.44

+0.23%↑

Home・Aktien・Cassava Sciences Inc

Cassava Sciences Inc

Open

BrancheGesundheitswesen

3.36 9.45

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.95

Max

3.44

Schlüsselkennzahlen
By Trading Economics
Einkommen	33M -11M
Verkäufe	840K 840K
EPS	-0.22
Gewinnspanne	-1,286.548
Angestellte	30
EBITDA	35M -11M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+175.86% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.3M 142M
Vorheriger Eröffnungskurs	-6.09
Vorheriger Schlusskurs	3.36

Nachrichtenstimmung

By Acuity

50%

167 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

1.56 / 1.7 Unterstützung & Widerstand

Cassava Sciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Nov. 2025, 16:56 UTC

Ergebnisse

Wichtige Markttreiber

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25. Nov. 2025, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. Nov. 2025, 23:47 UTC

Market Talk

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25. Nov. 2025, 22:39 UTC

Market Talk

Global Equities Roundup: Market Talk

25. Nov. 2025, 22:39 UTC

Market Talk

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25. Nov. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. Nov. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

25. Nov. 2025, 21:38 UTC

Ergebnisse

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. Nov. 2025, 21:31 UTC

Market Talk

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25. Nov. 2025, 21:27 UTC

Ergebnisse

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25. Nov. 2025, 21:20 UTC

Ergebnisse

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. Nov. 2025, 21:18 UTC

Ergebnisse

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25. Nov. 2025, 21:15 UTC

Ergebnisse

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. Nov. 2025, 20:16 UTC

Market Talk

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25. Nov. 2025, 18:42 UTC

Market Talk

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25. Nov. 2025, 18:25 UTC

Akquisitionen, Fusionen, Übernahmen

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25. Nov. 2025, 17:30 UTC

Market Talk

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25. Nov. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

25. Nov. 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

25. Nov. 2025, 16:33 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Financial Details Weren't Disclosed

25. Nov. 2025, 16:33 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25. Nov. 2025, 16:32 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25. Nov. 2025, 16:31 UTC

Akquisitionen, Fusionen, Übernahmen

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25. Nov. 2025, 16:30 UTC

Akquisitionen, Fusionen, Übernahmen

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25. Nov. 2025, 16:23 UTC

Ergebnisse

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25. Nov. 2025, 16:12 UTC

Market Talk

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25. Nov. 2025, 16:11 UTC

Market Talk

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25. Nov. 2025, 16:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. Nov. 2025, 16:10 UTC

Market Talk

Sterling Could Briefly Rise After Budget -- Market Talk

25. Nov. 2025, 16:10 UTC

Market Talk

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Peer-Vergleich

Kursveränderung

Cassava Sciences Inc Prognose

Kursziel

By TipRanks

175.86% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD 175.86%

Hoch 8 USD

Tief 8 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cassava Sciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cassava Sciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.56 / 1.7Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

167 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.